TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04954170

Intervention type: DIAGNOSTIC_TEST
Intervention: IRRTM
Description: IRRT at maximal 90° abduction and maximal external rotation is performed with the shoulder at maximal 90° rotation and the elbow flexed to 90° (Fig. 2). The patient is then asked to resist the external rotation force applied perpendicular to the forearm by the investigator. The test is considered positive if the patient could not hold the position or if he or she showed weakness of resisted internal rotation compared with the other side. It should be noted the maximal 90° abduction and maximal external rotation is active range of motion. Passive motion may affect the result of the test because of severe pain.

Intervention type: DIAGNOSTIC_TEST
Intervention: the lift-off test
Description: The lift-off test is performed by placing the hand of the affected arm on the back (at the position of the midlumbar spine) and asking the patient to internally rotate the arm to lift the hand off the back \[9\]. The test is considered positive if the patient is unable to lift the arm posteriorly off the back or if he or she performs the lifting manoeuvre by extending the elbow or the shoulder. Weakness is also as a positive result.

Intervention type: DIAGNOSTIC_TEST
Intervention: the belly-press test
Description: The belly-press test is performed with the arm at the side and the elbow flexed to 90°, by having the patient press the palm into his or her abdomen by internally rotating the shoulder \[3, 5\]. The test is considered positive (1) if the patient shows a weakness in comparison with the opposite shoulder or (2) the patient pushes the hand against the belly by wrist flexion, despite instruction to the contrary.
Study: NCT03156452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 500 mg and 250mg tablets for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 5mg tablets for oral administration
Study: NCT04501445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Summary of Rounds
Description: The summary was organized as follows for each of the most important ICU problems: 1) Description of the problem, 2) Ways the ICU team is addressing the problem i.e. consultations, diagnostic tests, and treatments. 3) An assessment of whether the problem is improving or worsening.
Study: NCT00597909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylacetate and sodium benzoate injection 10% / 10%
Description: 5.5 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylacetate and sodium benzoate injection 10% / 10%
Description: 2.75 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo solution (10% dextrose)
Description: Placebo solution (10% dextrose), IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
Study: NCT01091532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-396,082
Description: 100mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: given orally twice daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-396,082
Description: 300mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: given orally twice daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-396,082
Description: 1000mg given orally twice daily for 14 days~The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: given orally twice daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UK-396,082
Description: UK-396,082 given orally, once on Days 1 \& 14, and twice daily on Days 3-13.~The decision to proceed to the next higher dose will be made jointly by the Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts. Dependent on the emerging safety, tolerability and PK data, Cohort 4 may be recruited to study a higher (or lower) dose of UK-396,082 in order to characterize further the safety, toleration and PK and/or to define the maximum tolerated dose. The dose in Cohort 4 will be selected such that the predicted Cmax will not exceed 46 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: given orally, once on Days 1 \& 14, and twice daily on Days 3-13.
Study: NCT01935154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vx-001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03969758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: will receive tablet Ciprofloxacin (500 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefixime
Description: will receive tablet Cefixime (200 mg BDS) and tablet Metronidazole (800 mg TDS) for 2 weeks orally. Percutaneous aspiration or drainage of the liver abscess will be done when there is enough liquid content/pus amenable for aspiration or drainage. Percutaneous drainage or aspiration will be done in liver abscess with size of ≥ 5 cm and \<5 cm respectively.
Study: NCT00655798

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: plain yogurt and capsules containing cellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plain Yogurt + mix of anti-oxidants capsules
Description: plain yogurt and capsules containing mix of anti-oxidants

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Yogurt containing Lactobacillus helveticus
Description: Yogurt containing the probiotic Lactobacillus helveticus
Study: NCT02081469

Intervention type: OTHER
Group type: OTHER
Intervention: TDF
Description: To compare extend TDF 24 wks versus 48 wks prophylaxis efficacy in chemotherapy CHB patients

Intervention type: OTHER
Group type: OTHER
Intervention: TDF
Description: To compare extend TDF 24 wks versus 48 wks prophylaxis efficacy in chemotherapy CHB patients
Study: NCT00984230

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BSF
Description: feeding amount according to individual baby need

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BSF + Lactoferrin + Probiotics
Description: feeding amount according to individual baby need

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BSF + Lactoferrin + Probiotics + OS
Description: feeding amount according to individual baby need
Study: NCT02334969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naoxintong Capsule
Description: This is Naoxintong capsule,which is composed of Huangqi,Chishao,Danshen,Danggui, Chuanxiong,Taoren,Honghua,Ruxiang,Moyao,Jixueteng,Niuxi,Guizhi,Sangzhi,Dilong,Quanxie,etal.
Study: NCT04954170

Intervention type: DIAGNOSTIC_TEST
Intervention: the IRLS test
Description: IRLS test is evaluated with the affected arm of the patient was held by the examiner at maximum internal rotation \[10\]. The back of the hand is then passively lifted away from the body until almost full internal rotation is reached. Then, the patient is asked to actively maintain this position. The test is considered positive when the patient fails to maintain the position and the hand lagged.

Intervention type: DIAGNOSTIC_TEST
Intervention: the bear-hug test
Description: The bear-hug test is performed with the palm of one side placed on the opposite shoulder and fingers extended and the elbow positioned anterior to the body \[3\]. The patient is then asked to hold that position when the examiner tried to pull the patient's hand from the shoulder with an external rotation force applied perpendicular to the forearm. The test is considered positive if the patient could not hold the hand against the shoulder or if he or she showed weakness compared with the other side.

Intervention type: DIAGNOSTIC_TEST
Intervention: IRRT 0°
Description: IRRT at 0° abduction and 0° external rotation is performed with the arm at the side and the elbow flexed to 90° (Fig. 1). The patient is then asked to resist the external rotation force applied by the investigator. The test is considered positive if the patient could not hold the position at the side or if he or she showed weakness of resisted internal rotation compared with the other side. The test is negative if patients only complain of pain.

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic arthroscopy
Description: At the time of surgery, general anaesthesia was administered and the patient was placed in beach-chair position. A complete arthroscopic exploration of the glenohumeral joint and the subacromial space was performed through a standard posterior portal. The senior author performed a complete arthroscopic exploration. Arthroscopic evaluation of the rotator cuff was considered the gold standard for making the definitive diagnosis. Evaluation of the SSC was carried out with both a 30° arthroscope and a 70° arthroscope.
Study: NCT01444677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB12066
Description: MB12066 300mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MB12066
Description: MB12066 400mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MB12066
Description: MB12066 100mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MB12066
Description: MB12066 200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 300mg (single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
Study: NCT02820701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OMT
Description: Osteopathic Manipulative Treatment to low back region
Study: NCT01043900

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 30 daily sessions: each with 40 trains of 5 seconds at 10Hz, with a 25 second inter-train interval, at an intensity of 110% of motor threshold. Site: Right Dorsolateral Prefrontal Cortex

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 30 daily sessions: each with 40 trains of 5 seconds at 10Hz, with a 25 second inter-train interval, at an intensity of 110% of motor threshold. Site: Right Dorsolateral Prefrontal Cortex
Study: NCT02334969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo capsule has the same as Naoxintong capsule in the appearance, shape,colour and content tinct.
Study: NCT03138915

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HVPG measurement
Description: HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTA
Description: Radiomic features were extracted from CTA images.
Study: NCT02262130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Study: NCT01419171

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OMEGA™ Monorail Coronary Stent System
Description: All enrolled patients are treated with the OMEGA™ Monorail Bare Metal Coronary Stent System and followed for 12 months post-procedure.
Study: NCT01919372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedic assistance with a technological system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Study: NCT04118361

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HINTS Test
Description: The HINTS test is a clinical test composed of 3 oculomotor examinations:~* Search for high-frequency vestibulo-ocular reflex during a passive head impulse test~* Highlighting of spontaneous nystagmus: it must be sought without, then with Frenzel glasses because they allow to temporarily interrupt the ocular fixation.~* Vertical divergence~This test is performed at the patient's bedside in about 3 minutes. Presence of at least one of the three items of central locator value is sufficient to diagnose a central cause of VAS, including normal early brain imaging.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: STANDING Algorithm
Description: The STANDING algorithm consists of clinical elements that can be evaluated in about 10 minutes at the patient's bedside: two oculomotor examinations (Head Impulse Test and detection of a nystagmus), detection of ataxia and the practice of release maneuvers.
Study: NCT04674137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC8 100 mg
Description: 1 tablet of XC8 100 mg once daily in the morning during 12 weeks of treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet of placebo once daily in the morning during 12 weeks of treatment period.
Study: NCT01868269

Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone acetate
Description: First step:~immunosuppressive treatment with dexamethasone

Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone and cyclophosphamide
Description: second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide

Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone and rituximab
Description: third step (in case of insufficient response): immunosuppressive treatment with dexamethasone and rituximab
Study: NCT03709433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT groups and mobile app
Description: See arm description.
Study: NCT04024228

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains (QIV-SD)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
Study: NCT03491189

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lag screw fixation
Description: surgical fixation
Study: NCT01105351

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: folic acid plus B6 and B12
Description: folic acid 400 µg plus vitamin B12 plus B6

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: folic acid
Description: folic acid 400 µg
Study: NCT02477098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preoperative 0.5% ropivacaine hydrochloride preoperative
Description: Before surgery (Pre RSB) , a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: postoperative 0.5% Ropivacaine hydrochloride
Description: Before surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.
Study: NCT00163137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lasofoxifene
Description: lasofoxifene 0.25mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raloxifene
Description: raloxifene 60 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg/day
Study: NCT01252329

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: elective lymph node dissection
Description: This entails selective lymph node dissection in patients with negative lymph node exams. The nodes dissected are those that drain from the high risk cutaneous squamous cell cancer. Subsequent radiation and/or chemotherapy may be administered in a small percentage of subjects, depending on the result of the neck dissection.
Study: NCT03491189

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helical blade fixation
Description: surgical fixation
Study: NCT05167110

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Children assigned to the groups (ASD/ADHD) will be randomly prescribed placebo supplementation for 12 weeks (placebo subgroup).
Study: NCT01526226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory support HFNC
Description: In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory support HFNC
Description: In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory support NCPAP
Description: In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory support NCPAP
Description: In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
Study: NCT05167110

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Children assigned to the groups (ASD/ADHD) will be randomly prescribed supplementation with two GABA- and dopamine-producing strains at a total of 1 x 10 (9) CFU/capsule for 12 weeks (probiotic subgroup).
Study: NCT00539097

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juven (Ross Products) protein supplement
Description: Juven supplement oral x 3 weeks postop
Study: NCT00918723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study: NCT00679562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic Acid
Description: Application of occlusive patches containing test product. For 24 hours and repeat 2 weeks later for participants with no reaction to Lactacyd Radiance

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: Application of patches containing distilled water for 24 hours
Study: NCT02950623

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: titanium dioxide denture
Description: patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover design

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: titanium dioxide denture
Description: patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover design

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: rapid heat denture
Description: patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) according to the principle of crossover design

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rapid heat denture
Description: patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) according to the principle of crossover design
Study: NCT02795910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach education training
Description: Printed copies of the patient management tool (PMT) and outreach education training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No outreach education training
Description: Printed copies of the patient management tool (PMT) without outreach education training
Study: NCT04273243

Intervention type: GENETIC
Intervention: AT-GTX-501
Description: No study drug is administered in this study. Subjects who received AT-GTX-501 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
Study: NCT04215549

Intervention type: OTHER
Intervention: No intervention
Description: cross sectional study，no intervention